Sanofi (NASDAQ:SNY) Given Consensus Rating of “Hold” by Analysts

Sanofi (NASDAQ:SNY) has received an average rating of “Hold” from the fourteen analysts that are currently covering the company, Marketbeat reports. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $62.6667.

SNY has been the topic of a number of research reports. HSBC restated a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Finally, UBS Group restated a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th.

Sanofi Stock Down 2.2%

Shares of NASDAQ:SNY opened at $46.01 on Monday. The firm has a market capitalization of $112.22 billion, a P/E ratio of 12.78, a P/E/G ratio of 1.22 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.29 and a current ratio of 1.09. The stock has a 50 day moving average price of $47.73 and a 200-day moving average price of $48.60. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

Key Stories Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently bought and sold shares of the company. Flagship Harbor Advisors LLC purchased a new position in shares of Sanofi in the fourth quarter worth $25,000. Financial Consulate Inc. bought a new position in shares of Sanofi in the third quarter worth about $26,000. Ameritas Advisory Services LLC purchased a new stake in Sanofi in the 2nd quarter worth $28,000. Measured Wealth Private Client Group LLC bought a new position in Sanofi in the 3rd quarter worth approximately $29,000. Finally, Palisade Asset Management LLC purchased a new stake in shares of Sanofi in the third quarter worth about $30,000. Institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.